Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.74 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.74 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30317191 | 0.93 | CRBN (0.72) | CRBNDDB1DRD2SLC6A4 | |
| SCHEMBL25109405 | 0.92 | CRBN (0.70) | CRBNDDB1DRD2SLC6A4 | |
| SCHEMBL23842402 | 0.91 | CRBN (0.69) | CRBNDDB1DRD2SLC6A4 | |
| SCHEMBL21106269 | 0.91 | CRBN (0.78) | CRBNDDB1IKZF3HTT | |
| SCHEMBL21106898 | 0.91 | CRBN (0.78) | CRBNDDB1IKZF3HTT | |
| SCHEMBL21106896 | 0.91 | CRBN (0.78) | CRBNDDB1IKZF3HTT | |
| SCHEMBL24764282 | 0.90 | CRBN (0.73) | CRBNDDB1IKZF3 | |
| SCHEMBL24764283 | 0.90 | CRBN (0.73) | CRBNDDB1IKZF3 | |
| SCHEMBL23832938 | 0.88 | CRBN (0.70) | CRBNDDB1IKZF3 | |
| SCHEMBL21070982 | 0.88 | CRBN (0.70) | CRBNDDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-115776887-A | MDM2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2023-03-10 | — | — | CN | disclosed |
| WO-2022120118-A1 | NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2021188696-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2020206424-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | CRBN 171/4885DDB1 3993/4885DRD2 3228/4885 |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | CRBN 171/4885DDB1 3993/4885DRD2 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.